%PDF-1.3
%
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
12 0 obj
<>stream
Atypon Systems, Inc.; modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2017-02-20T07:23:05-08:00
2017-02-07T07:18:16+05:30
application/pdf
SCD-2016-0196-ver9-Numan_3P 1..3
uuid:90079d2d-8299-4fcc-9b39-756f33fcbaee
uuid:0b165795-29a4-45eb-abbd-8849de1f532b
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
9.9626 0 0 9.9626 62.022 464.9385 Tm
0 0 0 rg
0 Tc
0 Tw
[(Case)-341.2(1)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 447.0802 Tm
[(A)-278.4(22-year-old)-285.2(female)-282.1(followed)-281.8(since)-284.2(2004)-275.1(had)-280.9(symptoms)]TJ
-1.0137 -1.1116 TD
[(of)-301.7(severe)-297.9(dysautonomia,)-302.5(including)-299.5(frequent)-305(syncope,)-301.3(severe)]TJ
T*
[(headaches,)-462.5(and)-453.7(postural)-453.5(tachycardia.)-459.3(She)-453.6(had)-459.5(severe)-453.4(gas-)]TJ
0 -1.1174 TD
[(trointestinal)-604.7(symptoms)-604.3(of)-601.2(dysphagia,)-608.9(nausea,)-600.8(abdominal)]TJ
0 -1.1116 TD
[(pains,)-355.6(and)-350(diarrhea)-357.9(\(up)-354.6(to)-347.9(15)-353.5(times)-353.5(daily\).)-357(She)-349.9(was)-356.5(wheel-)]TJ
T*
[(chair)-249.8(bound)-247.4(by)-244.1(her)-246.3(OI.)-248.4(Head)-249.5(up)-244.1(tilt)-246.8(table)-250(test)-247.5(\(HUTT\))-252.6(before)]TJ
T*
[(MSC)-546.5(infusion)-550.3(showed)-549.9(tachycardia)-553.8(up)-543.6(to)-549.5(150)-544.7(bpm)-545.9(with)]TJ
0 -1.1174 TD
[(syncope)-453.3(and)-448(hypotension)-451.1(after)-451.4(4)-168.1(min)-448.2(of)-451.4(head)-450.2(up)-445.7(tilt.)-451.8(Ex-)]TJ
0 -1.1116 TD
[(tensive)-833.7(autoimmun)-8(e)-831.7(evaluation)-838.5(showed)-832.1(positive)-833.8(anti-)]TJ
T*
[(glutamic)-312.3(acid)-312.1(decarboxylase,)-317.2(antiparietal)-318(cell)-312.3(and)-309.7(antifolate)]TJ
0 -1.1174 TD
[(receptor)-363.7(antibodies,)-362.6(elevated)-365.1(serum)-359(cytokines,)-361.3(and)-361.6(antithy-)]TJ
0 -1.1116 TD
[(roid)-620.8(peroxidase)-619.2(antibodies.)-621.7(She)-620.6(was)-615.7(initially)-622.4(diagnosed)]TJ
T*
[(with)-305(polyarticular)-312(juvenile)-311(idiopathic)-307.6(arthritis.)-308.5(She)-303.8(received)]TJ
0 -1.1174 TD
[(multiple)-351.5(anti-inammatory)-346.4(and)-350(immunosuppressive)-351.5(agents;)]TJ
0 -1.1116 TD
[(however,)-394.5(her)-396.1(symptoms)-396.9(were)-393.5(only)-390.4(partially)-398.6(alleviated)-396.3(and)]TJ
T*
[(she)-424.7(continued)-421.4(to)-422.8(medically)-424(deteriorate.)-423.7(Her)-425.8(maternal)-422.7(aunt)]TJ
T*
[(had)-286.7(a)-290.2(similar)-286.7(clinical)-295(course)-285.2(and)-292.4(died)-287.9(in)-284.5(her)-286.7(early)-290.2(30s)-291.1(while)]TJ
0 -1.1174 TD
[(being)-242.9(treated)-247.6(at)-245.4(the)-246.5(NIH,)-244.6(Bethesda,)-247.1(MD.)-243.6(In)-244.1(September)-245(2014,)]TJ
0 -1.1116 TD
[(she)-292.3(received)-295.8(5)-294.8(million)-291.7(ASCs/kg)-291.6(by)-290.2(intravenous)-296.7(infusion.)-294.5(At)]TJ
T*
[(subsequent)-352.9(bimonthly)-351.4(evaluations)-349.9(after)-353.5(ASC)-350.6(therapy,)-347.6(there)]TJ
0 -1.1174 TD
[(was)-345(dramatic)-353.6(improvement)-345.4(of)-347.7(her)-344.3(multiple)-345.8(symptoms,)-348.5(par-)]TJ
0 -1.1116 TD
[(ticularly)-565.7(gastrointestinal)-562.9(complaints,)-565.4(headaches,)-560.4(syncope,)]TJ
T*
[(and)-378.8(subjectively)-374.1(improved)-379.9(stamina.)-377.6(Her)-373.9(inammato)-9(ry)-370.8(bio-)]TJ
0 -1.1174 TD
[(markers)-506.3(were)-502.9(repeated)-508.9(3)-502.2(months)-503.1(after)-509(ASC)-500.4(therapy)-505.5(and)]TJ
0 -1.1116 TD
[(showed)-469.2(improvement.)-469.8(After)-468.4(ASC)-471.6(therapy,)-468.6(she)-465(completed)]TJ
T*
[(30)-169.2(min)-292.6(of)-295.9(head)-300.5(up)-295.9(position)-297(with)-293.5(normal)-302.8(heart)-295.9(rate)-300.6(\(HR\))-294.2(and)]TJ
0 -1.1174 TD
[(blood)-414.6(pressure)-413.9(\(BP\))-414.2(responses)-420.6(and)-413.4(improved)-414.5(sympathetic/)]TJ
0 -1.1116 TD
[(parasympathetic)-300.2(tone)-293.7(depicted)-294.8(by)-290.2(fast)-293.5(Fourier)-291(mathematical)]TJ
T*
[(analysis)-339.3(of)-330.5(HR)-338.2(and)-332.8(BP)-331.4(variability)-337.6(\(Table)-338.5(1\).)]TJ
/F7 1 Tf
9.9626 0 0 9.9626 62.022 118.3181 Tm
[(Case)-341.2(2)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 100.5165 Tm
[(A)-324.5(7-year-old)-330.2(male)-324.9(was)-327.7(diagnosed)-329(with)-328.1(systemic)-329(juvenile)]TJ
-1.0137 -1.1174 TD
[(idiopathic)-486.2(arthritis)-483.6(with)-483.6(polyarthritis.)-480.1(Magnetic)-485.8(resonance)]TJ
0 -1.1116 TD
[(imaging)-402(of)-393.8(his)-400.7(knees)-399.3(and)-396.1(hips)-396(showed)-400.1(effusions.)-400.1(Multiple)]TJ
T*
[(therapies)-612.4(included)-610.4(nonsteroidal)-614.7(anti-inammatory)-617.1(agents)]TJ
0 -1.1174 TD
[(and)-246.4(cytotoxic)-243(agents.)-242.7(Symptoms)-247.2(increased)-244.9(and)-246.4(he)-239.5(developed)]TJ
25.504 67.9184 TD
[(abdominal)-382.4(pain)-380.1(and)-378.8(diarrhea.)-384.4(At)-377.6(5)-375.5(years)-382(of)-376.5(age,)-383.4(he)-377.7(devel-)]TJ
0 -1.1174 TD
[(oped)-431.8(hypotension)-433.8(and)-430.7(tachycardia)-438.6(at)-429.7(upright)-428.4(posture)-435(with)]TJ
0 -1.1116 TD
[(dizziness.)-483.2(Symptoms)-471.8(prevented)-480(attendance)-477.9(at)-475.8(school.)-471.9(His)]TJ
T*
[(family)-487.3(elected)-490.7(ASC)-483.1(treatment)-487.3(and)-482.5(he)-481.4(received)-491.6(5)-479.2(million)]TJ
T*
[(autologous)-461.5(ASCs/kg)-452.9(in)-451.6(September)-458.1(2014.)-457.1(He)-453.5(presented)-456.8(to)]TJ
0 -1.1174 TD
[(our)-383.4(center)-384.6(3)-381.2(months)-382.2(after)-382.3(his)-383.4(ASC)-379.4(therapy.)-382.2(OI)-383.2(symptoms,)]TJ
0 -1.1116 TD
[(arthri)-8(tic)-304.2(pain,)-314.4(and)-309.7(other)-306.3(symptoms)-310.5(improved)-310.8(such)-310.6(that)-311.1(anti-)]TJ
T*
[(inammato)-9(ry)-583.9(and)-586.2(immune)-586.3(modulatory)-583.9(agents)-590.6(were)-589.3(dis-)]TJ
0 -1.1174 TD
[(continued)-548.2(and)-545.9(he)-539(completed)-550.5(30)-163.5(min)-546.1(of)-543.6(HUTT)-544.2(test)-547(with)]TJ
0 -1.1116 TD
[(normal)-279.8(HR)-274.8(and)-275.2(BP)-273.8(responses)-282.3(and)-275.2(normal)-274.1(cerebral)-278.5(perfusion)]TJ
T*
[(by)-336.3(near-infrared)-341.5(spectroscopy.)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 313.0582 589.6628 Tm
[(Di)-8.2(scussion)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 571.8046 Tm
-.0214 Tc
[(We)-288.6(ha)-6.4(ve)-288.6(demo)-5.2(ns)-5(tra)-6.4(t).4(ed)-287.4(bo)-5.2(th)-287.4(by)-287.4(imp)-5.2(r).6(ov)-5.2(ed)-287.4(sym)-6.4(p).5(to)-5.2(ms)-287.2(and)-287.4(b).5(y)]TJ
-1.0137 -1.1116 TD
-.0216 Tc
[(l)-5.5(a)-.8(b)-5.4(o).3(ra)-6.6(tor)-5.4(y)-310.7(t)-5.5(e)-.8(s)-5.2(t).2(s)-316.2(t).2(he)-317.6(s)-5.2(a)-.8(fe)-6.6(ty)-316.4(and)-316.4(e)-.8(f)-5.4().5(c)-6.6(acy)-316.4(of)-316.4(au)-5.4(tol)-5.6(ogo)-5.4(us)-316.2(AS)-5.3(Cs)-316.2(in)]TJ
T*
[(t)-5.6(r).3(e)-6.7(a)-.9(ti)-5.6(ng)-276.2(tw)-6.4(o)-276.2(you)-5.5(ng)-276.2(pa)-6.7(ti)-5.7(ent)-5.6(s)-276(wit)-5.6(h)-276.2(aut)-5.6(o).2(im)-6.7(mun)-5.5(e)-277.4(sys)-5.3(t).1(em)-6.7(ic)-277.4(di)-5.6(sea)-6.7(s).4(e)]TJ
0 -1.1174 TD
-.0199 Tc
[(a)-4.9(n)2(d)-355.1(dysautonomia.)-351.6(Both)-355.1(cases)]TJ
12.3027 0 TD
-.0218 Tc
[(had)-357(a)-358.1(sev)-5.6(e)-1(re)-358.1(fo)-5.6(rm)-358.2(of)-356.9(dys)-5.4(aut)-5.7(o).1(-)]TJ
-12.3027 -1.1116 TD
-.0214 Tc
[(n)-5.2(o).5(mi)-5.4(a)-300.1(c)-.6(omp)-5.2(l).4(i)-5.3(cat)-5.3(ed)-299(by)-299(or)-298.9(s)-5(eco)-5.2(nd)-5.2(ary)-299(t)-5.3(o)-293.2(a)-6.4(ut)-5.3(oimm)-6.4(une)-300.1(p)-5.2(r).6(oc)-6.4(ess)-5(e)-.6(s)-5(.)]TJ
T*
-.0199 Tc
[(M)-4.6(e).9(dical)-240(therapy)-239.9(i)1.9(nitiated)-239.9(in)-239.9(both)]TJ
12.7865 0 TD
-.0174 Tc
[(p)4.5(a)3.4(ti)4.4(ent)4.4(s)-237.2(b)4.5(e)-2.4(f)4.6(o)4.5(re)-238.5(AS)4.7(C)-238.4(i)4.4(nf)4.6(us)4.7(i)4.4(o)-1.2(n)4.5(s)]TJ
-12.7865 -1.1174 TD
-.0216 Tc
[(w)-6.3(a)-.8(s)-414.2(i)-5.5(nte)-6.6(n).3(si)-5.5(ve,)-416.7(i).2(n)-5.4(c)-.8(lu)-5.4(din)-5.4(g)-414.4(mul)-5.5(tip)-5.4(le)-415.5(im)-6.6(mune)-415.5(m)-6.6(odu)-5.4(lat)-5.5(o).3(ry)-414.4(t)-5.5(h).3(er)-5.4(a-)]TJ
0 -1.1116 TD
-.017 Tc
[(pi)4.8(es)5.1(.)-406.3(W)2.7(e)-410.9(p)4.9(ro)4.9(p)4.9(o)-.8(s)5.1(e)-410.9(t)4.8(h)4.9(at)-404.1(sy)4.9(mpt)4.8(o)4.9(ms)-403.8(of)-404(dy)4.9(sau)4.9(t)-.9(o)4.9(n)4.9(o)-.8(mi)4.8(a)-410.9(i)4.8(mpr)5(o)4.9(ved)]TJ
T*
-.0215 Tc
[(a)-6.5(f).5(t)-5.4(e)-.7(r)-276(m)-6.5(odu)-5.3(lat)-5.5(i).3(o)-5.3(n)-276(of)-281.8(au)-5.3(toi)-5.4(mmu)-5.3(ne)-277.2(c)-6.5(o).4(mp)-5.3(one)-6.5(nts)-281.6(o).4(f)-281.7(t).3(h)-5.3(i).3(s)-281.6(s).6(y)-5.3(ndr)-5.3(ome)]TJ
T*
-.0181 Tc
[([4)3.8(].)-430.5(Human)-433.9(l)3.7(euk)3.8(o)3.8(c)-3.1(t)3.7(y)3.8(e)-435.1(a)2.7(nt)3.7(i)3.7(g)-1.9(en)3.8(-a)]TJ
12.775 0 TD
-.0201 Tc
[(ntigen)-435.9(D)-431(r)-3.9(ela)-5.1(t)1.7(ed)-435.9(\(H)-4.8(LA-DR\),)]TJ
-12.775 -1.1174 TD
-.0217 Tc
[(t)-5.6(h).2(e)-346.5(m)-1(ajo)-5.5(r)-339.5(h)-5.5(i).1(st)-5.6(oc)-6.7(ompa)-6.7(tib)-5.5(il)-5.6(ity)-345.3(com)-6.7(p).2(le)-6.7(x)-339.6(I).3(I)-345.3(c)-.9(e)-6.7(l).1(l)-339.7(s)-5.3(ur)-5.5(fac)-6.7(e)-340.7(r)-21.7(e)-2(c)-21.7(e)-3.2(p)-21.7(t)-1(o)-21.7(r)-6.6(,)]TJ
0 -1.1116 TD
0 Tc
[(in)15(te)19.6(ra)19.7(ct)19.5(s)-421.4(w)0(i)19.8(t)0(h)-411.3(i)0(m)19.5(m)0(u)19.6(n)0(e)-412.3(c)0(e)18.5(l)0(l)20.6(s)-421.4(to)-405.5(ca)18.5(us)15.3(e)-417(a)0(n)-412.3(i)0(m)19.5(m)0(u)19.6(n)0(e)-412.3(r)0(e)19.7(s)0(p)21(o)0(n)20.8(s)0(e)14.1(.)]TJ
T*
[(Owing)-485.4(to)-480.4(lack)-484.9(of)-480.2(HLA-DR)-489.5(expression)-485.3(on)-480.3(their)-485(surfaces,)]TJ
0 -1.1174 TD
[(MSCs)-363.1(have)-363.8(been)-358.1(demonstrated)-363.6(to)-359.4(be)-360.5(immune)-361.7(evasive,)-365.9(and)]TJ
0 -1.1116 TD
[(both)-724.5(autologous)-726.5(and)-724.4(allogeneic)-730.3(MSC)-725(treatments)-730.1(have)]TJ
T*
[(achieved)-388(promising)-379.8(outcomes)-380.9(in)-382.5(many)-381.2(clinical)-381.4(trials)-382.3([5,6].)]TJ
0 -1.1174 TD
[(Autologous)-363.3(MSC)-362.2(therapy)-361.5(is)-359.2(very)-362.6(safe)-357.8(and)-361.6(without)-360.3(causing)]TJ
0 -1.1116 TD
[(potential)-381.4(immune)-373.2(rejections)-383.3(after)-376.5(numerous)-373.8(repea)-9(ted)-373.2(treat-)]TJ
T*
[(ments)-7.8(.)-331.7(Numerous)-340.2(secretomes)-344.9(have)-335(been)-340.8(detected)-336.3(in)-336.4(MSCs,)]TJ
0 -1.1174 TD
[(which)-272.6(are)-264.8(associated)-269(with)-270.5(MSC)-264.3(immunomodulation,)-268.4(trophic)]TJ
0 -1.1116 TD
[(activities,)-461.9(angiogenesis,)-457.8(and)-459.5(antiapoptosis.)-458(High)-454.7(level)-457.4(e)-13.8(x)-6.9(-)]TJ
T*
.0119 Tc
[(press)5.2(ion)-334.8(o)-.7(f)-334.7(a)-1.9(n)5(t)-.8(i)4.9(-)-.7(in)5(ammat)4.9(or)5.1(y)-340.5(c)3.9(yto)5(k)-.7(i)4.9(n)-.7(es)-340.3(fr)5.1(om)-336(MS)5.2(Cs)5.2(,)-337.1(s)-.5(uch)]TJ
T*
.0121 Tc
[(as)-622.4(i)5.1(n)-.5(t)5.1(e)-1.7(r)5.3(l)-.6(eu)5.2(ki)5.1(n-)5.3(10)5.2(,)-624.9(i)5.1(nt)5.1(er)5.3(leuti)5.1(n)-.5(-)5.3(1)-.5(3)5.2(,)-624.9(macro)5.2(p)-.5(h)5.2(a)-1.7(g)5.2(e)-623.7(mig)5.2(r)-.5(atio)5.2(n)]TJ
0 -1.1174 TD
.4446 Tc
[(i)431.9(n)432(h)437.7(i)431.9(b)437.7(i)431.9(t)437.6(o)432(rf)437.8(a)430.8(c)436.6(t)431.9(o)432(r)437.8(,)3.4(a)430.8(n)437.7(dt)431.9(r)437.8(a)430.8(n)437.7(s)432.2(f)432(o)437.7(r)432(m)436.5(i)431.9(n)437.7(gg)432(r)437.8(o)432(w)436.9(t)431.9(hf)437.8(a)430.8(c)436.6(t)431.9(o)437.7(r)]TJ
/F9 1 Tf
20.8847 0 TD
0 Tc
(b)Tj
/F4 1 Tf
.5644 0 TD
.4412 Tc
[(,p)434.3(l)428.5(a)433.2(y)428.6(s)]TJ
-21.4491 -1.1116 TD
.0121 Tc
[(ver)5.3(y)-553.4(impo)5.2(rt)5.1(an)5.2(t)-553.6(r)-.5(o)5.2(l)-.6(es)-553.3(in)-553.4(i)5.1(n)-.5(h)5.2(i)-.6(bi)5.1(ti)5.1(on)-553.4(o)5.2(f)-553.4(in)5.2(ammat)5.1(io)5.2(n)-553.4(a)-1.7(n)5.2(d)]TJ
T*
.013 Tc
[(im)4.9(mu)6.1(nom)4.9(o)6.1(dul)6(at)6(io)6.1(n)-374(b)6.1(y)-368.2(r).4(ea)5(ct)6(in)6.1(g)-374(w)5.3(it)6(h)-374(m)4.9(os)6.3(t)-368.4(o).4(f)-368.2(t).3(h)6.1(e)-375.2(i)6(m)-.8(m)4.9(u).4(n)6.1(e)]TJ
0 -1.1174 TD
[(cel)6.1(ls)6.4(,)-410.8(i)6.1(nc)5.1(lu)6.2(di)6.1(ng:)-402.8(T)-409.6(c)5.1(el)6.1(ls,)-405(B)-403.7(ce)5.1(lls)6.4(,)-410.8(n)6.2(at)6.1(ur)6.3(al)-408.6(k)6.2(i).4(l)6.1(l).4(e)5.1(r)-408.4(ce)5.1(ll)6.1(s,)-405(an)6.2(d)]TJ
0 -1.1116 TD
.0072 Tc
[(d)-5.4(e)-6.6(nd)-5.4(ri)-5.5(ti)-5.5(c)-357.9(c)-6.6(el)-5.5(ls)-362.3(th)-5.4(ro)-5.4(u)-5.4(g).3(h)-356.8(v)-5.4(ar)-5.4(i)-5.5(o)]TJ
11.9226 0 TD
.0132 Tc
[(us)-350.6(m)5.1(e)-.6(c)5.2(h).6(an)6.3(is)6.5(ms)6.5(,)-353.1(s).8(u)6.3(c)-.6(h)-350.8(a)-.6(s)-350.6(c)-.6(e)5.2(l).5(l)6.2()]TJ
-11.9226 -1.1116 TD
.0073 Tc
[(c)-6.5(e)-6.5(l).3(l)-385.6(c)-6.5(on)-5.3(ta)-6.5(ct)-391.3(an)-5.3(d)-385.5(t).3(h)-5.3(e)-386.6(r)-5.3(e)-.7(l)-5.4(e)-.7(a)-6.5(s)-5.1(e)-386.6(o).4(f)-385.4(c)-6.5(he)-6.5(mo)-5.3(ki)-5.4(n)-5.3(e)-.7(s)-385.3(a)-6.5(nd)-391.2(cy)-5.3(to)-5.3(ki)-5.4(n)-5.3(e)-.7(s)]TJ
0 -1.1174 TD
.0068 Tc
[(i)-5.9(n)-334.1(v)-5.8(i)-5.9(vo)-339.9([7)-5.8(].)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 313.0582 228.1322 Tm
0 Tc
[(Conc)-11.5(lusion)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 210.2739 Tm
[(The)-420.4(favorable)-416.6(clinical)-421.8(response)-419.7(in)-417(these)-416.7(two)-419(young)-414.5(pa-)]TJ
-1.0137 -1.1116 TD
[(tients)-307.5(warrants)-299.9(further)-302.6(clinical)-306.6(trials)-301.7(using)-304.9(either)-302.9(autologous)]TJ
0 -1.1174 TD
[(or)-365(allogeneic)-367.4(MSCs)-368.9(for)-360.3(autoimmune)-367.4(diseases)-368.9(could)-363.9(be)-360.5(de-)]TJ
0 -1.1116 TD
[(signed)-612.5(for)-602.2(randomized,)-612.5(double-blind,)-605.7(single-dose)-613.3(versus)]TJ
T*
[(multiple-dose)-375.3(infusions,)-376.1(while)-370.7(evaluating)-377.8(patient)-373.3(outcomes)]TJ
0 -1.1174 TD
[(at)-251.2(a)-244.2(time)-243.2(course)-250.6(up)-244.1(to)-244.2(24)-244.1(months)-243.9(and)-246.4(even)-248.6(longer)-244(to)-250(evaluate)]TJ
0 -1.1116 TD
[(the)-327.1(role)-328.2(of)-324.7(MSC)-321.9(therapy)-326.9(on)-324.7(autonomic)-324.8(nervous)-325.4(system)-331.3(and)]TJ
T*
[(immune)-338.7(dysfunctions,)-334.4(which)-336(may)-334(be)-337.4(actually)-335.2(interrelated.)]TJ
/F1 1 Tf
9.9626 0 0 9.9626 313.0582 107.3763 Tm
[(Aut)-8(hors)-338.8(Disclosu)-12.8(re)-332(Sta)-8.2(tement)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 89.5181 Tm
[(M.T.N.,)-423.2(I.J.B.,)-415.3(and)-419.2(A.K.)-419.8(have)-421.4(no)-416.9(conict)-419.1(of)-416.9(interest)-420.2(or)]TJ
-1.0137 -1.1116 TD
[(disclo)-7.8(sures)-582.2(for)-585(this)-586.2(study.)-584.8(J.Y.)-585.7(is)-583.9(employed)-588.5(by)-583.9(Celltex)]TJ
T*
[(Therapeuti)-10.2(cs)-751.9(Corporation)-751.8(and)-753.2(she)-753(contributed)-757.8(for)-752(the)]TJ
0 -1.1174 TD
[(methods)-338.3(part)-334(of)-336.2(this)-332.8(study.)]TJ
ET
62.022 709.512 239.131 .22681 re
f
62.022 512.22 239.131 .28345 re
f
62.022 680.485 239.131 .22681 re
f
BT
/F6 1 Tf
9.845 0 0 9.845 64.8 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F6 1 Tf
1.2496 0 TD
[(Summary)-332(of)-337(Biomarkers)-333.8(of)-331.2(Immune)-338.5(System)]TJ
-4.4801 -1.0135 TD
[(and)-332(Autonomic)-335.4(Nervous)-336.6(System)-334.6(by)]TJ
/F4 1 Tf
16.4118 0 TD
(HUTT)Tj
/F6 1 Tf
3.0002 0 TD
[(for)-338(Case)]TJ
/F4 1 Tf
4.2728 0 TD
(1)Tj
/F10 1 Tf
-13.9472 -1.8715 TD
[(Before)-337.7(MSC)]TJ
.9732 -1.0135 TD
(therapy)Tj
7.8604 1.0135 TD
[(After)-335.7(MSC)]TJ
.6392 -1.0135 TD
(therapy)Tj
/F4 1 Tf
-19.2623 -1.9061 TD
[(Cytokine)-332.9(13)-3647.1(19)-163.2(pg/mL)-4810.1(6)-168(pg/mL)]TJ
0 -1.0135 TD
[(Cytokine)-332.9(6)-4147.1(8)-162.2(pg/mL)]TJ
/F8 1 Tf
17.3044 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
[(5)-168(pg/mL)]TJ
.4377 -1.0135 TD
(\(normal\))Tj
-18.2949 -1.0077 TD
[(HR)-309(during)-311.3(HUTT)]TJ
.9905 -1.0135 TD
[(test)-339.3(\(upright\))]TJ
7.6646 1.0135 TD
[(150/min)-5306.3(95/min)]TJ
-8.6551 -2.027 TD
[(Syncope)-337.3(during)]TJ
.9905 -1.0077 TD
[(HUTT)-336.2(test)]TJ
7.6646 1.0077 TD
[(Yes)-333(at)-331.6(4.5)-166.6(min)]TJ
.9905 -1.0077 TD
[(of)-330.2(upright)]TJ
7.6589 1.0077 TD
(Completed)Tj
.9905 -1.0077 TD
[(30)-169(min)-332.5(upright)]TJ
0 -1.0135 TD
[(with)-333.4(no)]TJ
T*
(syncope)Tj
-18.2949 -1.0135 TD
(Cerebral)Tj
.9905 -1.0077 TD
[(perfusion)-338.3(by)]TJ
0 -1.0135 TD
[(NIRS)-333.8(during)]TJ
T*
[(HUTT)-336.2(test)]TJ
7.6646 3.0348 TD
(Severely)Tj
.9905 -1.0077 TD
[(decreased)-337.1(by)]TJ
/F8 1 Tf
0 -1.0135 TD
(>)Tj
/F4 1 Tf
.5528 0 TD
[(30%)-332.2(of)-330.2(her)]TJ
-.5528 -1.0135 TD
(baseline)Tj
7.6589 3.0348 TD
[(No)-336.8(signicant)]TJ
.9905 -1.0077 TD
(decrease)Tj
0 -1.0135 TD
(\()Tj
/F8 1 Tf
.334 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
(10%)Tj
-.8868 -1.0135 TD
(decrement\))Tj
-18.2949 -1.0135 TD
[(Sympathetic)-338.4(tone)]TJ
.9905 -1.0077 TD
[(by)-336(Fourier)]TJ
0 -1.0135 TD
(analysis)Tj
7.6646 2.0212 TD
(Severely)Tj
.9905 -1.0077 TD
(increased)Tj
/F8 1 Tf
0 -1.0135 TD
(>)Tj
/F4 1 Tf
.5528 0 TD
(80%)Tj
7.106 2.0212 TD
[(Mild)-333.4(increase)]TJ
.9905 -1.0077 TD
(\()Tj
/F8 1 Tf
.334 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
(50%\))Tj
8.7511 0 0 8.7511 70.0157 500.4282 Tm
[(HR,)-432.6(heart)-440.8(rate;)-439.6(HUTT,)-435.3(head)-438.2(up)-438.2(tilt)-437.3(table;)-438.6(MSC,)-439.2(mesenchymal)]TJ
-.9134 -1.0236 TD
[(stem)-334.6(cell;)-336.1(NIRS,)-331.5(near-infrared)-337.4(spectroscopy.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
47.3965 0 TD
[(NUMAN)-335.4(ET)-338.7(AL.)]TJ
ET
endstream
endobj
33 0 obj
<>stream
/GS1 gs
BT
/F1 1 Tf
9.9626 0 0 9.9626 59.7543 725.0455 Tm
0 0 0 rg
0 Tc
0 Tw
[(Ref)-7.4(erenc)-8.2(es)]TJ
/F4 1 Tf
9.2951 0 0 9.2951 59.7543 708.7747 Tm
[(1.)-500.4(Stewart)-509.1(JM.)-505(\(2000\).)-499.6(Autonomic)-505.7(nervous)-506.8(system)-502.4(dysfunc-)]TJ
1.2503 -1.1284 TD
[(tion)-603.3(in)-603.5(adolescents)-613.2(with)-604.8(postural)-603.4(orthostatic)-606.9(tachycardia)]TJ
T*
[(syndrome)-329.6(and)-334(chronic)-328.3(fatigue)-327.8(syndrome)-335.7(is)-328.2(characterized)-333.7(by)]TJ
0 -1.1223 TD
[(attenuated)-608.2(vagal)-600.2(Baroreex)-599.6(and)-602.4(potentiated)-603.5(Sympathetic)]TJ
0 -1.1284 TD
[(vasomotion.)-338.7(Pediatr)-336.8(Res)-331.8(48:218226.)]TJ
-1.2503 -1.1223 TD
-.0247 Tc
[(2)-24.7(.)-525.1(Arno)5.7(ld)-457.9(AC,)-457.8(K)-459.5(Ham)6.1(a)1.5(n,)-457.8(EM)-457.1(Garlan)5.7(d,)-457.8(V)-459.5(R).9(aj,)-457.8(W)1.3(D)-459.5(D)-2(u)5.7(pon)5.7(t,)-457.8(I)]TJ
1.2503 -1.1284 TD
-.0251 Tc
[(Biagg)5.3(i)-.3(o)5.3(n)-.8(i,)-263(D)-264.7(R).5(oberts)6.1(o)-.8(n)-263.1(a)1.1(nd)-263.1(SR)-267.9(Raj.)-263(\(2)5.3(01)5.3(5\).)-269.1(C)6.6(ogn)5.3(iti)5.8(ve)-267.3(d)5.3(y)-.8(sfun)5.3(c-)]TJ
0 -1.1223 TD
-.0254 Tc
[(tio)5(n)-153.6(i)-.6(n)-153.6(p)-1.1(o)5(s)-.3(tural)-153(t)-.6(ach)5(ycardia)-151.7(s)-.3(yn)5(drom)5.4(e.)-159.7(C)6.3(lin)-153.6(Sci)-153(\()-3.5(Lon)5(d)-1.1(\))-155.9(1)5(28)5(:39)5()-1.1(4)5(5)-1.1(.)]TJ
-1.2503 -1.1284 TD
0 Tc
[(3.)-500.4(Bernardo)-311.8(ME)-306.4(and)-309.6(WE)-311.5(Fibbe.)-306.2(\(2013\).)-310.6(Mesenchymal)-308.6(stromal)]TJ
1.2503 -1.1223 TD
[(cells:)-293.3(sensors)-297.6(and)-291.3(switchers)-297.4(of)-289.3(inammation.)-291(Cell)-295.1(Stem)-293.3(Cell)]TJ
0 -1.1284 TD
(13:392402.)Tj
-1.2503 -1.1223 TD
[(4.)-500.4(Krampera)-458.7(M,)-450.8(S)-454.4(Sartoris,)-456.2(F)-454.4(Liotta,)-450.6(A)-453.1(Pasini,)-457.4(R)-450.2(Angeli,)-456.9(L)]TJ
1.2503 -1.1284 TD
[(Cosmi,)-363.5(A)-361.6(Andreini,)-361.9(F)-362.9(Mosna,)-363.2(B)-358.7(Bonetti,)-368.2(et)-357.7(al.)-363.8(\(2007\).)-365.4(Im-)]TJ
0 -1.1223 TD
[(mune)-425.2(regulation)-425.2(by)-421.1(mesenchymal)-424.8(stem)-423.7(cells)-427.9(derived)-425.9(from)]TJ
0 -1.1284 TD
[(adult)-339.2(spleen)-331.1(and)-334(thymus.)-334.5(Stem)-336(Cells)-337(Dev)-335.6(16:797810.)]TJ
-1.2503 -1.1223 TD
[(5.)-500.4(Ankrum)-455.7(JA,)-452.4(JF)-453.6(Ong)-453.4(and)-456(JM)-450(Karp.)-454(\(2014\).)-456.9(Mesenchymal)]TJ
1.2503 -1.1284 TD
[(stem)-509.1(cells:)-512.9(immune)-509.9(evasive,)-512.4(not)-506.1(immune)-509.9(privileged.)-510.7(Nat)]TJ
0 -1.1223 TD
[(Biotechnol)-336.2(32:256260.)]TJ
-1.2503 -1.1284 TD
-.02 Tc
[(6)-20(.)-520.4(Zhao)-264.1(S,)-257.9(R)-262.8(W)-.1(ehner,)-257.9(M)-257.3(B)-.5(ornha)]TJ
12.5522 .0244 TD
0 Tc
()Tj
.366 -.0244 TD
-.0193 Tc
[(u)5(s)-.3(er,)-263.3(R)-256(Wassmut)5.5(h,)-257.2(M)-262.7(B).2(ach)5(mann)]TJ
-11.6678 -1.1223 TD
-.0191 Tc
[(and)-269.3(M)-268.6(Schmi)5.7(t)-.4(z.)-269.2(\(201)5.2(0\).)-269.2(I)-3.3(m)5.6(m)-.5(un)5.2(omo)5.2(dul)5.7(atory)-269.3(p)-.9(rop)5.2(e)1(rt)5.7(ies)-268.4(o)-.9(f)-271.6(m)5.6(es-)]TJ
27.0135 23.1466 TD
-.02 Tc
[(enc)-6(h)4.3(ymal)-336.7(stromal)-336.7(cells)-336.4(and)-337.3(t)-1.3(heir)]TJ
13.1621 0 TD
-.0204 Tc
[(the)-6.4(r)1.5(apeutic)-335.8(consequenc)-6.5(es)-336.8(for)]TJ
-13.1621 -1.1223 TD
-.0185 Tc
[(i)6.3(mmun)5.8(e)1.6(-m)6.2(ediated)-244.3(d)-.3(iso)5.8(r)-2.7(d)5.8(e)1.6(rs.)-244.2(S)2.9(tem)-250(C)1(ells)-243.4(Dev)-250.4(1)5.8(9:6)5.8(0)-.3(7)5.8(61)5.8(4.)]TJ
-1.2503 -1.1284 TD
0 Tc
[(7.)-500.4(Blaber)-235.4(SP,)-237.9(RA)-238.4(Webster,)-240.4(CJ)-236(Hill,)-238.4(EJ)-239.2(Breen,)-235.9(D)-239.6(Kuah,)-238.2(G)-233.5(Vesey)]TJ
1.2503 -1.1223 TD
[(and)-352.3(BR)-351.4(Herbert.)-356.7(\(2012\).)-347.1(Analysis)-357.8(of)-350.3(in)-353.5(vitro)-349.5(secretion)-355.8(pro-)]TJ
0 -1.1283 TD
[(les)-451.5(from)-456.1(adipose)-453.2(derived)-456.4(cell)-453.1(populations.)-454.6(J)-450.6(Transl)-459.2(Med)]TJ
0 -1.1223 TD
(10:172.)Tj
9.843 0 0 9.843 438.803 642.1038 Tm
[(Address)-331.9(correspondence)-343.5(to:)]TJ
/F10 1 Tf
-.1498 -1.1116 TD
[(Prof.)-337.3(Mohammed)-335.3(T.)-332.7(Numan)]TJ
1.0828 -1.1174 TD
[(Department)-337.7(of)-336.4(Pediatrics)]TJ
-.6105 -1.1116 TD
[(McGovern)-336.6(Medical)-333.9(School)]TJ
-8.3573 -1.1116 TD
[(The)-332.6(University)-343.7(of)-330.6(Texas)-335.8(Health)-337.2(Science)-335(Center)]TJ
6.9923 -1.1116 TD
[(6410)-332.7(Fannin)-336.2(Street,)-335(Suite)-335.2(425)]TJ
4.3659 -1.1174 TD
[(Houston,)-334.5(TX)-331.5(77030)]TJ
-9.3365 -2.2232 TD
(E-mail:)Tj
/F4 1 Tf
3.3982 0 TD
(mohammed.t.numan@uth.tmc.edu)Tj
-1.342 -2.2808 TD
[(Received)-285.3(for)-279.7(publication)-285.7(July)-280.8(4,)-281(2016)]TJ
-2.396 -1.1116 TD
[(Accepted)-285.2(after)-284.4(revision)-280.7(December)-286.2(12,)-282.1(2016)]TJ
-6.6006 -1.1116 TD
[(Prepublished)-286.1(on)-278.7(Liebert)-282.2(Instant)-285.4(Online)-279.6(XXXX,)-282(XX,)-283.8(XXXX)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(DYSAUTONOMIA)-342.9(AND)-330.9(MESENCHYMAL)-340.6(STEM)-338.2(CELL)-334.5(THERAPY)-24091.8(3)]TJ
ET
endstream
endobj
53 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
54 0 obj
<>stream
h\Wy\S9Eb(cωUQkں֊[K
EDP a' [YdWA\p*ժ]Ӫu.ҙ9;;}/y}Y3"6nٸeQdt0/J-wfy i3<TӡY/|PױP.ffIG^]lX"
D } ˏc1@$e2|Ry)~A?Z_
SӗB;qqX.L %O+yX!,zZZbȊ`6XXۃX{XeLRXA,ZɊfY! +9{K33 awls_9u`>˴}!A!C:C~z|zwĨGM1PIcDތR+PC:Bv=Wԕ'Um42_ziXe^ڴ}3c!1Ϲ:XPs3߅WfwCs;-Et6VZ1g%GkT44|Ci]0w.мL0D1^^;>!y2[fѲXMu6۳-Q`
8b\A?'~4_MW)|zyPHɾ~(K].?ٌE
F"c6$Q\=eq
w0;{{X*[${~ mžOf''DHzBܿbxwь.mCJvdGZaװoZ{J٨T&A3ZC;ƁvރhZ ]@1sy:A*#wIVo)Ƙcu3?WT˘0W<8;cy{ohgZ&AEv.puc*`~yL̪+"}RB%.,̊WPS:ę1}`/Cz%~k bB};U0!DnR+OWv*9%Y1m24Ǵhx }YdG&TbQ"o˩!Zф%&lٌ0}3a 0lj+;̘|we2mIT
g`lCnHA>5$lDwdDqsIlOYFf*'`1Tb6'P,Ylk%
BiR2nJn//(P+
C=jlt_0?A_0v3.Ϩ~F*Vjޯq0Qok>L}bu|l0%I
n6;o_Q}a'hc4I>^#,pOhn1=ce!51erX/:_6K7a
T@Wok2P84mƃzf͎ud\ [|m=py[3{jE)˕
)QդQ}lđtNcMw5G+lZf]
`l8/U'QloCf"<6
{w6h^t͝'O`茮tB+aRZPgMm[fhcgQ[SmD LPZpGӭ&ӏzT|YΔAbi8E]Xp W{UI4an^KB`oJ$@aeVdY,0Ӥ\^VZ.>D.Y84@@P6">+b=_~_[娪dV!1a7kZg}JBg??X~egO\k1U{OAKZL6n$G%Un$dwvS@{
eި5%HqӀ1F紹Tx4Q
_z
O-j88Ϝw1gEcaJaC8~^|9~t%~xPH((41[UOw֜vPnԬdhtCP&&SLL3NwC
`'(QjB(5Ok_ѵ*kyPʜ9n~SK:$H <5:TnSvW2\!h~_CjƔ;Baw;yA!L.IX.nHqϿ2Sw;ƾOahTB/"$.ug>* QlP|k;b\m~Ag,IB
RdYq}(l
0reABu"m2FfhZ+n2J$V|bOFCDv֕H4
^KOƒ)q=c_r;3
DМ{=ҴEMjkz,jTWRfD>YG
s̄tws~^
XgҚrK1.oox<ʱMxZsKseV[@}
Σĭ5%
/xqe**kK2FBPˮc9ݞ?6Nti."
]8ݩ2BW[0lo&knR`f/t:TH-g ǫVd%%YYwWy"Rei=bu2>?XhUJسO}|)na'
rJ2naɑ̨5o!F94VEK1@ɺO>\u#ufgp$Ԫh;P[#W/?F9j07S(GFVXFIK}NJsưY?\9v۳dkZNE"ȷ柾ttqF=v
ggzloUxO~8N;{8)!<>Ux1$@3/G;W$:1:+Xg[Ui
kj-y>v
r}]"
EG1t@K}fD,1m&--Ƹ2$5q^)}Q %~Mʦ2$tJv>R]gkvy2&Φay/y ;ÌR4Ƶ}"O|^KEQD2aS:y7?[kN9j0
e+:}`1T9M3*KvrυKkQVj6ƴ÷؟LaUUBj*SKE8adRjjkяLx}}ՒOIDRأ{-6e%UrBe||[m{5V{9nw#ZPZJ;Q־ 1$ʖ)**v>_cvQ9:xUM*+If#}
)BY:FZ)Y-6PkdG]kKGqCI\⎈8ZsN9QBڮjlN]뤫(@3 ryk1)-+ny_C]k3=84rD/UCX j\eGI@Si
;)ҔS- 3ɺ24R5}R}*o"P2VQjn0` 5)C
endstream
endobj
56 0 obj
<>stream
8;Z\7#nhk5%*\`9aEK[G&I:C^:po_u,ALJ,"%5iI`;otSnh2uCAL,tRg-Z^s\EgXk
2*VDOr#iJXXK@9Hka-Wj+N%3Bh_m7AIORu3VnEbZs2nC9^:%-HQ%ObAB4Yi+o!otF
2h8Cc4jTf1bFA0S!4V=i):HIo>U2W#:J-nAkY[M>H=VG%1p,d[H5&Yb0pG7F?cusP
3p!l-2f:h@"ujoh.@5(hI+4?Bin;=PUtd(TH:h42)!=asUf9j9bDS>q+cn(e$OeUE
o"7'8(JTWo`RfmO?hqYlh&PNrgCYB7f7%;IG-3ZHk%hQqZ+f"o>e^0'4a9N3Ye3(M
kucN36afZBFr\QcMc9&k2/WjlG[ru<]&frkkdft/IU1LQGUFF7C+Wh!\,cdt1pHF@qRi/hV7Fr[c/#0gL,J1>J+pZEaYpD-X&mk6#
E:K4BVWcTUP*bLm1B?Z.Y-e~>
endstream
endobj
21 0 obj
<>stream
8;Z\7=cUBR#gN<$aE9seg4J!$fH6l_WcDVI(.&uWi"qro>)V5l/S7pd?3J_=4U/jI
aOK<=]b0V480\UE/kA:a.q-8_/(a%rjM:=TAskiHU+!Zl;UIr$JR*ja"2V:UC:_.D
G`dT865dB.QVki,G[*-dbcDQVXodTEuYJJQZ@q*f>+;-$"!fqNq,Z_s=W)7ZBmo)CAfJoMe
)!VX"k@3[MCBBRH$WO3*E_*;+J9;c;>u,^p_1LGLe:GUt+0@Q'i31%IO.NV>Y+S=&
h50LJO>lH]aXCSD#!3lsNOiW:`!WC)W,d4p4-SiLM=oU]:A$bDZ[jmi9P)I88K4g5
endstream
endobj
34 0 obj
<>stream
8;Z\tD%=K,#XlB+"hDo*D)Z/D:r(n_aa67@IONF!O7MnVkh3DK
U+76\?cbFQ]=aG1a/Cl8Vn=Z$!<<*"z!-eU
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>stream
HTn0}WQVպX5mm$b+A~tCC)GYg%,)3i,IwE!h8KT4gJfnFYn@.rq7?Bь7hIR~ZQF˛Sy|Դ